



#30
Dmt
2-13-03

Docket No.: PF112P2D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hu et al.

Application No.: 09/257,272

Filed: February 25, 1999

For: Vascular Endothelial Growth Factor 2

RECEIVED

FEB 7 2003

TC 1700

Group Art Unit: 1647

Examiner: R. Landsman

**EIGHTH SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
Washington, DC 20231

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to the Statutory Declarations listed as references FB-FV on the attached Form SB/08. Copies of two Statutory Declarations referenced herein as FB and FC are enclosed.

The Statutory Declarations cited on the attached Form SB/08 as references FD-FV have all been previously submitted to the Patent Office in the above-captioned application. Applicants wish to have the Statutory Declarations considered by the Examiner and marked in the record as such. Therefore, Applicants are submitting the instant Information Disclosure Statement with these Statutory Declarations listed on the accompanying Form SB/08. No copies of Statutory Declarations referenced as FD-FV are being provided because copies of these Statutory Declarations have been submitted previously.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request

02/05/2003 ANABI1 00000035 083425 09257272

01 FC:1806 180.00 CH

that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), because this Supplemental Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent & Trademark Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the required fee, as itemized on the Fee Transmittal Sheet submitted concurrently herewith.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, or credit any overpayment, to our Deposit Account No. 08-3425.

Dated: Feb-4, 2003

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(301) 610-5764

MMW/MJP/AKR/lcc/ba